Balance of pro- and anti-inflammatory cytokines in young patients who passed active Immunization against SARS-CoV-2 during the COVID-19 Pandemic
- Authors: Li Y.A.1, Dmitrachenko M.N.1, Markelova E.V.1, Korolev I.B.1, Kostinov M.P.2,3, Bondar L.I.4
-
Affiliations:
- Pacific State Medical University
- I. Mechnikov Research Institute of Vaccines and Sera
- I.M. Sechenov First Moscow State Medical University
- Regional Clinical Hospital No. 2, Center for the Prevention and Control of AIDS and Infectious Diseases
- Issue: Vol 14, No 3 (2024)
- Pages: 459-464
- Section: SHORT COMMUNICATIONS
- URL: https://journals.rcsi.science/2220-7619/article/view/262064
- DOI: https://doi.org/10.15789/2220-7619-BOP-16848
- ID: 262064
Cite item
Full Text
Abstract
In 2019, the COVID-19 pandemic began and changed the world. Coronavirus SARS-CoV-2 has caused widespread illness and death around the world. In this regard, vaccination become the most important tool for creating herd immunity. Our study analyzed the dynamics of pro- and anti-inflammatory cytokines and antibodies to SARS-CoV-2 in the blood serum of young patients before and after vaccination against COVID-19. The study group included 76 young men. Determination of IL-1β, IL-4, IL-6, IL-8, IL-10, IL-17, IFNγ, TNFα and IgM and IgG antibodies to COVID-19 in venous blood sera was carried out twice, by ELISA using the test systems of Vector-Best Company, Novosibirsk. The first blood samples were carried out before vaccination, the second — 1 month after vaccination against COVID-19. The results were processed using STATISTICA 8.0. The vaccinated people were monitored for 6 months after vaccination. Levels of indices before vaccination: IL-1β (5.6 pg/ml (Q₂₅–Q₇₅ = 3.1–14.2); IL-4 (1.02 pg/ml (Q₂₅–Q₇₅ = 0.75–1.28); IL-6 (27.8 pg/ml (Q₂₅–Q₇₅ = 7.1–59.9); IL-8 (29.9 pg/ml (Q₂₅–Q₇₅ = 19.51–32.14); IL-10 (4.47 pg/ ml (Q₂₅–Q₇₅ = 1.84–14.75); IL-17 (7.33 pg/ml (Q₂₅–Q₇₅ = 6.82–8.58); IFNγ (0.7 pg/ml (Q₂₅–Q₇₅ = 0.4–0.9); TNFα (3.9 pg/ml (Q₂₅–Q₇₅ = 2.2–6.4). Levels of indices after vaccination: IL-1β (1.6 pg/ml (Q₂₅–Q₇₅ = 1.4- 2.2); IL-4 (0.84 pg/ml (Q₂₅–Q₇₅ = 0.59–1.12); IL-6 (1.2 pg/ml (Q₂₅–Q₇₅ = 0.6–1.7); IL-8 (10.1 pg/ml (Q₂₅–Q₇₅ = 3.8–28.9); IL-10 (5.84 pg/ml (Q₂₅–Q₇₅ = 1–9.99); IFNγ (0.6 pg /ml (Q₂₅–Q₇₅ = 0.3–0.8); TNFα (0.6 pg/ml (Q₂₅–Q₇₅ = 0.3–1.9). Both before and after vaccination against SARS-CoV-2, different distributions of cytokine levels were identified with a downward trend, but despite this, strong correlations were observed between many of them, which indicates an increase in the tension of the immune system in response to vaccination. When calculating the ratio of pro- and anti-inflammatory cytokines, its two-fold decrease was revealed, which reflects a decrease in the levels of pro-inflammatory cytokines after vaccination. The level of IgG antibodies to COVID-19 exceeded the protective level: more than 14 times in 98% of subjects. Further research into the impact of SARS-CoV-2 vaccination on innate immunity will allow us to reconsider the current vaccination strategy and determine the best approach to preventing COVID-19.
Full Text
##article.viewOnOriginalSite##About the authors
Yulia A. Li
Pacific State Medical University
Author for correspondence.
Email: julianochka160188@gmail.com
PhD (Medicine), Infectious Diseases Doctor, Major of Medical Service, Lecturer
Russian Federation, Vladivostok, Ostryakova pr., 2M. N. Dmitrachenko
Pacific State Medical University
Email: julianochka160188@gmail.com
Student
Russian Federation, Vladivostok, Ostryakova pr., 2E. V. Markelova
Pacific State Medical University
Email: julianochka160188@gmail.com
DSc (Medicine), Professor, Head of the Department of Normal and Pathological Physiology, Pacific State
Russian Federation, Vladivostok, Ostryakova pr., 2I. B. Korolev
Pacific State Medical University
Email: julianochka160188@gmail.com
PhD (Medicine), Colonel of Medical Service, Head of the Military Training Center of the Pacific
Russian Federation, Vladivostok, Ostryakova pr., 2M. P. Kostinov
I. Mechnikov Research Institute of Vaccines and Sera; I.M. Sechenov First Moscow State Medical University
Email: julianochka160188@gmail.com
RAS Corresponding Member, DSc (Medicine), Professor, Head of the Laboratory of Vaccine Prophylaxis and Immunotherapy, Mechnikov Research Institute of Vaccines and Sera
Russian Federation, Moscow; MoscowL. I. Bondar
Regional Clinical Hospital No. 2, Center for the Prevention and Control of AIDS and Infectious Diseases
Email: julianochka160188@gmail.com
Clinical Laboratory Diagnostics Doctor
Russian Federation, VladivostokReferences
- Костинов М.П. Иммунопатогенные свойства SARS-CoV-2 как основа для выбора патогенетической терапии // Иммунология. 2020. Т. 41, № 1. С. 83–91. [Kostinov M.P. Immunopathogenic properties of SARS-CoV-2 as a basis for the choice of pathogenetic therapy. Immunologiya = Immunologiya, 2020, vol. 41, no. 1, pp. 83–91. (In Russ.)] doi: 10.33029/0206-4952-2020-41-1-83-91
- Костинов М.П., Свитич О.А., Маркелова Е.В. Потенциальная иммунопрофилактика COVID-19 у групп высокого риска инфицирования. Временное пособие для врачей. М.: Группа М.Д.В., 2020. 64 c. [Kostinov M.P., Svitich O.A., Markelova E.V. Potential COVID-19 immunization in high-risk groups. Provisional guide for physicians. Moscow: MDV Group, 2020. 64 p. (In Russ.)]
- Костинов М.П., Хромова Е.А., Костинова А.М. Может ли вакцинация против гриппа быть неспецифической профилактикой SARS-CоV-2 и других респираторных инфекций? // Инфекционные болезни: новости, мнения, обучение. 2020. Т. 9, № 3. С. 36–40. [Kostinov M.P., Khromova E.A., Kostinova A.M. Can influenza vaccination be a nonspecific prevention of SARS-CoV-2 and other respiratory infections? Infektsionnye bolezni: novosti, mneniya, obuchenie = Infectious Diseases: News, Opinions, Training, 2020, vol. 9, no. 3, pp. 36–40. (In Russ.)] doi: 10.33029/2305-3496-2020-9-3-36-40
- Крылова Н.В., Леонова Г.Н., Павленко Е.В. Особенности цитокинового профиля на ранних стадиях инфицирования вирусом клещевого энцефалита у вакцинированных и невакцинированных людей // Тихоокеанский медицинский журнал. 2012. № 4. C. 78–81. [Krylova N.V., Leonova G.N., Pavlenko E.V. Features of the cytokine profile in the early stages of infection with tick-borne encephalitis virus in vaccinated and unvaccinated people. Tihookeanskiy medicinskiy zhurnal = Pacific Medical Journal, 2012, no. 4, pp. 78–81. (In Russ.)]
- Kaminska D., Deborska-Materkowska D., Koscielska-Kasprzak K., Mazanowska O., Remiorz A., Poznanski P., Durlik M., Krajewska M. Immunity after COVID-19 recovery and vaccination: similarities and differences. Vaccines, 2022, vol. 10, no. 7: 10⁶8. doi: 10.3390/vaccines100710⁶8
- La Sala L., Gandini S., Bruno A., Allevi R., Gallazzi M., Senesi P., Palano M.T., Meregalli P., Longhi E., Sommese C., Luzi L., Trabucchi E. SARS-CoV-2 Immunization Orchestrates the Amplification of IFNγ-Producing T Cell and NK Cell Persistence. Front. Immunol., 2022, vol. 13: 798813. doi: 10.3389/fimmu.2022.798813
- Pierce J.D., Shen Q., Cintron S.A., Hiebert J.B. Post-COVID-19 Syndrome. Nurs. Res., 2022, vol. 71, no. 2, pp. 164–174. doi: 10.1097/NNR.0000000000000565
- Principi N., Autore G., Ramundo G., Esposito S. Epidemiology of Respiratory Infections during the COVID-19 Pandemic. Viruses, 2023, vol. 15, no. 5: 1160. doi: 10.3390/v15051160
- Wang Z., Schmidt F., Weisblum Y., Muecksch F., Barnes C.O., Finkin S., Schaefer-Babajew D., Cipolla M., Gaebler C., Lieberman J.A., Oliveira T.Y., Yang Z., Abernathy M.E., Huey-Tubman K.E., Hurley A., Turroja M., West K.A., Gordon K., Millard K.G., Ramos V., Da Silva J., Xu J., Colbert R.A., Patel R., Dizon J., Unson-O’Brien C., Shimeliovich I., Gazumyan A., Caskey M., Bjorkman P.J., Casellas R., Hatziioannou T., Bieniasz P.D., Nussenzweig M.C. mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants. Nature, 2021, vol. 592, no. 7855, pр. 616-622. doi: 10.1038/s41586-021-03324-6
Supplementary files
